cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Nurhadiyahya
Contact Email
nurhadiyahya@ugm.ac.id
Phone
+6289672800034
Journal Mail Official
ijpther@ugm.ac.id
Editorial Address
Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada Jl. Farmako Sekip Utara, Yogyakarta 55281
Location
Kab. sleman,
Daerah istimewa yogyakarta
INDONESIA
Indonesian Journal of Pharmacology and Therapy
Published by Universitas Gadjah Mada
ISSN : -     EISSN : 2745455X     DOI : https://doi.org/10.22146/ijpther.4468
Core Subject : Science,
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Neuroscience
Indonesian Journal of Pharmacology and Therapy (IJPTher ) is a scientific journal which managed by Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFI) and Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada. IJPTher is an open-access, and double-blind peer-reviewed journal published twice Issues a year. IJPTher aims to communicate high-quality articles in the fields of pharmacology. IJPTher publishes original articles, review articles, case reports and book reviews in the fields of pharmacology including basic pharmacology, clinical pharmacology, pharmacotherapy, pharmacoepidemiology, pharmacogenetics, pharmacogenomics, pharmacoeconomic, toxicology and toxicogenomics.
Arjuna Subject : Pharmacology, Toxicology and Pharmaceutics - Pharmacology, Toxicology and Pharmaceutics (Lain-Lain)
Articles 5 Documents
 1 
Search results for , issue "Vol 2 No 1 (2021)" : 5 Documents clear
Hepatoprotective effect of chewable tablet of Centella asiatica (L.) Urb extractin Wistar rats induced by high fat diets Akrom; Feri Anggita Hastanto; Laela hayu Nurani
Indonesian Journal of Pharmacology and Therapy Vol 2 No 1 (2021)
Publisher : Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFI) and Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (188.14 KB) | DOI: 10.22146/ijpther.1128

Abstract

Gotukola or Centella asiatica (L.) Urban contains high flavonoids which well known as fatty liver protector. This study aimed to evaluate the hepatoprotective effect of chewable tablet of C. asiatica (L.) Urb extract (CTCE) in Wistar rats induced by high fat diets. Twenty-one Wistar male rats aged 8-12 weeks with body weight ranging from 100-150 g were used in this study. Rats were randomly divided into seven groups i.e. Group 1 as normal control, rats were given standard food, Group 2 as high fat diets control, rats were induced high fat diets (HFD),Group 3 as positive control, rats were induced HFD and given simvastatin, Group 4 as placebo control, rats were induced HFD and given placebo, Group 5-7 as treatment group, rats were induced HFD and given CTCE at doses of 100, 200 and 300 mg/kg BW, respectively. The HFD induction was conducted for five weeks andthe CTCE was given for one week in the last week of the induction. At the end of the intervention, blood triglyceride levels and SGPT as well SGOT activities were examined. Analysis of variance (ANOVA) with confidence interval of 95% (p<0.05) was applied. The results showed that the HFD induction increased the serum triglyceride levels and SGPT activity. The serum triglyceride levels and SGPT activity of Group 2 were significantly higher than Group 1 (p<0.05). Furthermore, the simvastatin and CTCE administration reduced the serum triglyceride levels and SGPT activity. The serum triglyceride levels and SGPT activity of Group 3, 5, 6and 7 were significantly lower than Group 2 and 4 (p<0.05). In addition, the serum triglyceride levels and SGPT activity of Group 5, 6 and 7 were significantly lower than Group 3 (p<0.05). In conclusion, CTCE can reduce the serum triglyceride levels and SGPT activity in Wistar rats induced by HFD.
Potential targeted therapy: The role of MicroRNAs in breast cancer metastasis via epithelial-mesenchymal transition and cancer stem cell regulation Pamungkas Bagus Satriyo
Indonesian Journal of Pharmacology and Therapy Vol 2 No 1 (2021)
Publisher : Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFI) and Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (636.691 KB) | DOI: 10.22146/ijpther.1184

Abstract

Abstract In the advancement of breast cancer treatment, metastatic breast cancer is remaining as an incurable disease. It contributes to almost 90% of cancer-related death in breast cancer cases. Epithelial to Mesenchymal Transition (EMT) is a serial change of the epithelial cell to gain the mesenchymal-like phenotype. In cancer, the cells that undergo the EMT lose the adherent junction protein, cell polarity, and gain the invasive phenotype. Recent studies showed that the EMT induces the cancer stem cell-like phenotypes in cancer cells. These cells possess self-renewal ability, and multi-lineage differentiation capacity to generate the new bulk of tumor during cancer distant metastasis. Both EMT and cancer stem cells take responsibility in drug-resistant, and relapse cases in breast cancer. In the last decades, a new type of non-coding RNA, microRNA (miR) shows have an important role in the normal physiological and pathophysiological condition such as cancer. Recent studies revealed that the EMT is regulated by microRNAs. In this review, we discussed the microRNAs regulation on the EMT process through TGF-β, and Wnt signaling pathways in breast cancer. Understanding of microRNA regulation in EMT in breast cancer metastasis gives a chance to explore a new therapy approach to improve the prognosis of breast cancer patients. In addition, we also explored several potential approaches targeting microRNA as a new approach of cancer treatment. Keywords: breast cancer, microRNA, EMT, metastasis, targeted therapy.
Synthesis of 3-carbethoxy-4(3’-chloro-4’-hydroxy) phenyl-but-3-en-2-one and its cytotoxicity evaluation against cancer cell carrying mutant p53 Jeffry Julianus; Mustofa; Jumina
Indonesian Journal of Pharmacology and Therapy Vol 2 No 1 (2021)
Publisher : Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFI) and Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (541.609 KB) | DOI: 10.22146/ijpther.1211

Abstract

Overexpression of mutant p53 in cancer cell inactivates the p53 pathways to execute apoptosis and cell cycle arrest. This study aimed to synthesize new kardiena derivative compound, 3-carbethoxy-4(3’-chloro-4’-hydroxy)phenyl-but-3-en-2-one, to reactivate the p53 pathways to execute apoptosis and cell cycle arrest. Characterization of the synthetic compound employing melting point, IR, EI-MS, 1H-NMR, and 13C-NMR spectra revealed 3-carbethoxy-4(3’-chloro-4’-hydroxy)phenyl-but-3-en-2-one was successfully synthesized from 3-chloro-4-hydroxybenzaldehyde and ethyl acetoacetate using dimethylamine as a catalyst. This compound had antiproliferative activity against the WiDr cells which carried mutant p53. Its antiproliferative activity was better than 5’-FU as a reference standard to treat colon cancer. Increasing WiDr cell accumulation in the G2-M phase, the active form of caspase-3, and inducing apoptosis demonstrated the ability of 3-carbethoxy-4(3’-chloro-4’-hydroxy)phenyl-but-3-en-2-one to reactivate p53 pathways to execute apoptosis and cell cycle arrest in cancer cells carrying mutant p53.
Drugs repurposing for COVID-19: phase III clinical trial evaluation Woro Rukmi Pratiwi
Indonesian Journal of Pharmacology and Therapy Vol 2 No 1 (2021)
Publisher : Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFI) and Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (232.093 KB) | DOI: 10.22146/ijpther.1228

Abstract

World Health Organization (WHO) has announced coronavirus disease 2019 (COVID-19) as a global pandemic which is the largest public health crisis in this century. The spread of COVID-19 is still not well-controlled even become global health threat. As new disease, the specific drugs for COVID-19 have not been available, yet. Face of this condition, repurposing existing drugs become the best options in order to meet the urgently need of the effective drugs. In this article, the clinical trial results of some drugs for the treatment of COVID-19 included hydroxychloroquine, chloroquine, lopinavir/ritonavir, remdesivir, oseltamivir, favipiravir, and corticosteroids were reviewed. Hydroxychloroquine, choloquine and lopinavir/ritonavir were shown to be ineffective. Therefore, they were excluded from the list of drugs for the tratment of COVID-19 by WHO and the National Agency of Drug and Food Control of Republic of Indonesia (NCDE NA-DFC RI). Furthermore, NA-DFC RI has issued an emergency use authorization (EUA) for the use of remdesivir and favipiravir for the treatment of COVID-19.
The resistance status of Aedes aegypti larvae to Temephos in Depok, Sleman, Yogyakarta Mia Munawaroh Yuniyanti; Sitti Rahmah Umniyati; Ernaningsih
Indonesian Journal of Pharmacology and Therapy Vol 2 No 1 (2021)
Publisher : Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFI) and Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (165.291 KB) | DOI: 10.22146/ijpther.1329

Abstract

There are still many cases of dengue hemorrhagic fever and tend to increaseover time. One strategy to reduce the increase in cases of dengue infection isto eradicate Aedes aegypti as a vector using insecticides. The use of insecticidesfor a long time can cause resistance. The purpose of this study was to determinethe resistance status of Aedes aegypti larvae against temephos in Depok, Sleman.This quasi experimental test was carried out on 3rd instar larvae of aedesaegypti from RW 9 and 10 Minomartani, Depok, Sleman. The treatment groupwas exposed 0.02 ppm temephos for 24 hours. The analysis was presented in theform of percentage of larval mortality and resistance categories based on WHOguidelines. The mortality percentage of Aedes aegypti larvae in RW 9 was 100%,while the mortality from RW 10 was 97%. Aedes aegypti larvae in Depok district,Sleman are still susceptible to temephos at a dose of 0.02 ppm.

Page 1 of 1 | Total Record : 5

 1 

Filter by Year

2021 2021


Reset
Filter By Issues
All Issue Vol 4 No 2 (2023) Vol 4 No 1 (2023) Vol 3 No 3 (2022) Vol 3 No 2 (2022) Vol 3 No 1 (2022) Vol 2 No 3 (2021): Special Issue: COVID-19 Vol 2 No 3 (2021) Vol 2 No 2 (2021) Vol 2 No 1 (2021) Vol 1 No 2 (2020) Vol 1 No 1 (2020) More Issue